Trials / Unknown
UnknownNCT03426956
Glucose Absorption and Gut Hormone Secretion After Gastric Bypass
Impact of Canaglifloxin on Gut Hormone Secretion After Gastric Bypass
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Hvidovre University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To investigate the impact of canagliflozin on secretion of gut hormones, in particular glucagon-like peptide 1 (GLP-1) in gastric bypass operated patients.
Detailed description
Glucose is a potent stimulus for GLP-1 secretion after gastric bypass surgery and the SGLT-1 transporter appears to be crucial for this response. The study will investigate the effects of SGLT-1/SGLT-2 inhibition (by canagliflozin) on secretion of GLP-1 and other gut hormones after gastric bypass surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Glucose | Ingestion of glucose (50 g) dissolved in 200 ml water. |
| DIETARY_SUPPLEMENT | Glucose + Canagliflozin | Ingestion of glucose (50 g) dissolved in 200 ml water combined with the SGLT-1/SGLT-2 inhibitor canagliflozin. |
Timeline
- Start date
- 2018-02-08
- Primary completion
- 2019-05-01
- Completion
- 2019-05-01
- First posted
- 2018-02-08
- Last updated
- 2018-02-09
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT03426956. Inclusion in this directory is not an endorsement.